Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioaffinity Technologies Inc (BIAF)

Bioaffinity Technologies Inc (BIAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,983
  • Shares Outstanding, K 4,499
  • Annual Sales, $ 9,360 K
  • Annual Income, $ -9,040 K
  • EBIT $ -10 M
  • EBITDA $ -9 M
  • 60-Month Beta 2.45
  • Price/Sales 0.14
  • Price/Cash Flow N/A
  • Price/Book 0.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1101 +19.81%
on 12/29/25
1.7400 -23.56%
on 12/10/25
-0.3300 (-19.88%)
since 12/09/25
3-Month
1.1101 +19.81%
on 12/29/25
3.5000 -62.00%
on 10/16/25
-1.5700 (-54.14%)
since 10/09/25
52-Week
1.1101 +19.81%
on 12/29/25
46.5300 -97.14%
on 04/01/25
-26.3030 (-95.19%)
since 01/08/25

Most Recent Stories

More News
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets...

BIAF : 1.3300 (+3.10%)
BIAFW : 0.2568 (unch)
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced...

BIAF : 1.3300 (+3.10%)
BIAFW : 0.2568 (unch)
bioAffinity Technologies Reports Third Quarter 2025 Financial Results

Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet

BIAF : 1.3300 (+3.10%)
BIAFW : 0.2568 (unch)
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Australian patent strengthens global patent portfolio

BIAF : 1.3300 (+3.10%)
BIAFW : 0.2568 (unch)
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

Visit the CyPath® Lung team at Booth #2242 October 19-22

BIAF : 1.3300 (+3.10%)
BIAFW : 0.2568 (unch)
bioAffinity Technologies Secures Patent for Lung Cancer Detection

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. bioAffinity...

BIAF : 1.3300 (+3.10%)
bioAffinity Regains Nasdaq Compliance, Ensures Continued Trading

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. bioAffinity...

BIAF : 1.3300 (+3.10%)
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

U.S. award protects AI-built platform and adds to growing international patent portfolio

BIAF : 1.3300 (+3.10%)
BIAFW : 0.2568 (unch)
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung , the Company’s...

BIAF : 1.3300 (+3.10%)
BIAFW : 0.2568 (unch)
bioAffinity Technologies Announces $1.8M Direct Offering

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

BIAF : 1.3300 (+3.10%)

Business Summary

bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO.

See More

Key Turning Points

3rd Resistance Point 1.4440
2nd Resistance Point 1.4092
1st Resistance Point 1.3696
Last Price 1.3300
1st Support Level 1.2952
2nd Support Level 1.2604
3rd Support Level 1.2208

See More

52-Week High 46.5300
Fibonacci 61.8% 29.1796
Fibonacci 50% 23.8200
Fibonacci 38.2% 18.4605
Last Price 1.3300
52-Week Low 1.1101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar